New Mechanism Found That Could Reverse Drug Resistance in Colorectal Cancer
Scientists identify how the HMBOX1-HACE1-ATG5 axis suppresses autophagy to restore 5-FU chemosensitivity in colorectal cancer.
484 articles in this topic
Scientists identify how the HMBOX1-HACE1-ATG5 axis suppresses autophagy to restore 5-FU chemosensitivity in colorectal cancer.
A randomized trial shows hydroxychloroquine and everolimus can dramatically reduce dormant tumor cells in breast cancer survivors, potentially preventing relapse.
A pyruvate metabolism enzyme suppresses leucine catabolism to keep mTOR active in liver cancer — and blocking it shrinks tumors in vivo.
A bespoke DNA vaccine tailored to individual glioblastoma tumors shows promising immunological activity in one of oncology's hardest challenges.
Blocking CysLTR1 reprograms immunosuppressive neutrophils and reverses resistance to anti-PD1 checkpoint therapy in mice.
A newly identified lipid mediator may explain why immune cells fail to fight MASH-driven liver cancer, opening therapeutic targets.
MAIT cells appear to provide protective immune surveillance in Lynch syndrome carriers who haven't developed colorectal cancer, suggesting new risk stratification tools.
A comprehensive review in CA Cancer J Clin maps the molecular biology, treatment strategies, and equity gaps in high-grade serous ovarian cancer.
New research reveals how lung cancer subclones develop distinct immune evasion strategies, complicating immunotherapy response.
New research reveals how corticotroph pituitary tumors develop resistance to temozolomide through clonal selection of high MGMT-expressing cells.
A multinational study of 4,913 patients finds EBRT delivers survival outcomes comparable to surgery and ablation for early hepatocellular carcinoma.
Adding targeted radiation to standard therapy reduced progression by 46% across multiple cancer types in the EXTEND trial.